NATCO PHARMA LIMITED (INDIA)
"Anastronat" contains same Drug / Molecule called “Anastrozole”.It belongs to a class of medications called Nonsteroidal aromatase inhibitors. Anastrozole binds reversibly to the aromatase enzyme through competitive inhibition, inhibits the conversion of androgensto estrogens in peripheral tissues . It lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
Anastronat is used for treating (treatment following surgery with or without radiation) breast cancer in postmenopausal women. It is effective in the off-label reduction of estrogens in men thus, minimizing the chances of benign prostatic hyperplasia, gynecomastia and hypogonadism in them
SIDE EFFECTS :
- Serious side effects include skin reactions such as lesions, ulcers or blisters, allergic reactions with swelling of the face, lips, tongue, and/or throat and changes in blood tests of the liver function, including inflammation of the liver with symptoms that may include a general feeling of not being well, with or without jaundice, liver pain or liver swelling.
- Common side effects in women taking Anastronat included: hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, pain, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and lymphedema.
- Co-administration of Anastronat and tamoxifen in breast cancer patients reduced Anastrozole plasma concentration.
- Estrogen-containing therapies should not be used with Anastronat as they may diminish its Pharmacological action.
- Anastronat do not alter the exposure and anticoagulant activity of both R- and S-warfarin
- A single dose of Anastronat that results in life-threatening symptoms has not been established. The treatment must be symptomatic, as there is no specific antidote to overdosage. In the management of an overdose, consider that multiple agents may have been taken.
- Vomiting may be induced if the patient is alert. Dialysis may be helpful because Anastronat is not highly protein bound.
- Anastronat is a prescription drug and should be used under proper medical guidance and advice.
- Caution should be exercised in patients with history of stomach problem, liver, kidney, or heart disease during pregnancy and breastfeeding.
- In women with pre-existing ischemic heart disease, an increased risk of ischemic cardiovascular events was observed upon administration of Anastronat.
- There is a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.
- Incidence of elevated serum cholesterol in patients administered Anastronat compared to patients receiving tamoxifen.
- Anastronat may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer.
1X10 Tablets (Strips)
Store at roomtemperature (25 °C).